BD Veritor System for Rapid Detection of Flu A + B Labratory Kit
Device Facts
| Record ID | K160164 |
|---|---|
| Device Name | BD Veritor System for Rapid Detection of Flu A + B Labratory Kit |
| Applicant | Becton, Dickinson & CO |
| Product Code | PSZ · Microbiology |
| Decision Date | Feb 25, 2016 |
| Decision | SESE |
| Submission Type | Special |
| Regulation | 21 CFR 866.3328 |
| Device Class | Class 2 |
Indications for Use
The BD Veritor™ System for Rapid Detection of Flu A+B is a rapid chromatographic immunoassay for the direct and qualitative detection of influenza A and B viral nucleoprotein antigens from nasopharyngeal wash, aspirate, and swab in transport media samples from symptomatic patients. The BD Veritor System for Rapid Detection of Flu A+B is a differentiated test, such that influenza A viral antigens can be distinguished from influenza B viral antigens from a single processed sample using a single device. The test is to be used as an aid in the diagnosis of influenza A and B viral infections. A negative test is presumptive and it is recommended that these results be confirmed by viral culture or an FDA-cleared influenza A and B molecular assay. Outside the U.S. a negative test is presumptive and it is recommended that these results be confirmed by viral culture or a molecular assay cleared for diagnostic use in the country of use. FDA has not cleared this device outside the U.S. Negative test results do not preclude influenza viral infection and should not be used as the sole basis for treatment or other patient management decisions. The test is not intended to detect influenza C antigens.
Device Story
Rapid chromatographic immunoassay for qualitative detection of influenza A and B viral nucleoprotein antigens. Input: nasopharyngeal wash, aspirate, or swab in transport media. Process: specimen mixed with RV Reagent C (mucolytic) in reaction tube; applied to test device; antigens bind to antibody-conjugated detector particles; complexes migrate to reaction area. Device features five zones: positive control, negative control, Flu A test line, Flu B test line, and background zone. Reader uses proprietary algorithm to subtract nonspecific signal (negative control) from test line signals (Flu A/B). Output: positive/negative result for Flu A and B. Used in laboratory settings. Benefits: provides rapid, differentiated diagnosis of influenza A and B; active negative control feature improves accuracy over visual interpretation.
Clinical Evidence
Bench testing only. Reactivity study conducted using two influenza A/H5 strains (A/Northern Pintail/Washington/40964/2014 and A/Gyrfalcon/Washington/41088-6/2014). Acceptance criterion was a positive instrument read in 3/3 replicates. Both strains were successfully detected at specified concentrations.
Technological Characteristics
Immunochromatographic assay; utilizes mucolytic RV Reagent C. Device contains five spatially-distinct zones: positive control, negative control, Flu A test line, Flu B test line, and background zone. Employs antibody-conjugated detector particles. Reader-based interpretation using proprietary signal subtraction algorithm.
Indications for Use
Indicated for symptomatic patients requiring qualitative detection of influenza A and B viral nucleoprotein antigens from nasopharyngeal wash, aspirate, or swab in transport media. Not intended for influenza C detection.
Regulatory Classification
Identification
An influenza virus antigen detection test system is a device intended for the qualitative detection of influenza viral antigens directly from clinical specimens in patients with signs and symptoms of respiratory infection. The test aids in the diagnosis of influenza infection and provides epidemiological information on influenza. Due to the propensity of the virus to mutate, new strains emerge over time which may potentially affect the performance of these devices. Because influenza is highly contagious and may lead to an acute respiratory tract infection causing severe illness and even death, the accuracy of these devices has serious public health implications.
Special Controls
*Classification.* Class II (special controls). The special controls for this device are:(1) The device's sensitivity and specificity performance characteristics or positive percent agreement and negative percent agreement, for each specimen type claimed in the intended use of the device, must meet one of the following two minimum clinical performance criteria: (i) For devices evaluated as compared to an FDA-cleared nucleic acid based-test or other currently appropriate and FDA accepted comparator method other than correctly performed viral culture method: (A) The positive percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent. (B) The negative percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent. (ii) For devices evaluated as compared to correctly performed viral culture method as the comparator method: (A) The sensitivity estimate for the device when testing for influenza A must be at the point estimate of at least 90 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 80 percent. The sensitivity estimate for the device when testing for influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent. (B) The specificity estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent. (2) When performing testing to demonstrate the device meets the requirements in paragraph (b)(1) of this section, a currently appropriate and FDA accepted comparator method must be used to establish assay performance in clinical studies. (3) Annual analytical reactivity testing of the device must be performed with contemporary influenza strains. This annual analytical reactivity testing must meet the following criteria: (i) The appropriate strains to be tested will be identified by FDA in consultation with the Centers for Disease Control and Prevention (CDC) and sourced from CDC or an FDA-designated source. If the annual strains are not available from CDC, FDA will identify an alternative source for obtaining the requisite strains. (ii) The testing must be conducted according to a standardized protocol considered and determined by FDA to be acceptable and appropriate. (iii) By July 31 of each calendar year, the results of the last 3 years of annual analytical reactivity testing must be included as part of the device's labeling. If a device has not been on the market long enough for 3 years of annual analytical reactivity testing to have been conducted since the device received marketing authorization from FDA, then the results of every annual analytical reactivity testing since the device received marketing authorization from FDA must be included. The results must be presented as part of the device's labeling in a tabular format, which includes the detailed information for each virus tested as described in the certificate of authentication, either by: (A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where the analytical reactivity testing data can be found; or (B) In the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access. (4) If one of the actions listed at section 564(b)(1)(A)-(D) of the Federal Food, Drug, and Cosmetic Act occurs with respect to an influenza viral strain, or if the Secretary of Health and Human Services (HHS) determines, under section 319(a) of the Public Health Service Act, that a disease or disorder presents a public health emergency, or that a public health emergency otherwise exists, with respect to an influenza viral strain: (i) Within 30 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation, the manufacturer must have testing performed on the device with those viral samples in accordance with a standardized protocol considered and determined by FDA to be acceptable and appropriate. The procedure and location of testing may depend on the nature of the emerging virus. (ii) Within 60 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation and continuing until 3 years from that date, the results of the influenza emergency analytical reactivity testing, including the detailed information for the virus tested as described in the certificate of authentication, must be included as part of the device's labeling in a tabular format, either by: (A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where analytical reactivity testing data can be found, but separate from the annual analytical reactivity testing results; or (B) In a section of the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access.
Predicate Devices
- BD Veritor™ System for Rapid Detection of Flu A+B Laboratory kit (k120049, k121797, k132256, k132693)
Related Devices
- K132256 — BD VERITOR SYSTEM FOR THE RAPID DETECTION OF FLU A+B · Becton, Dickinson and Company · Aug 7, 2013
- K132693 — BD Veritor System Flu A+B Assay · Becton, Dickinson and Company · Oct 2, 2013
- K160161 — BD Veritor System for Rapid Detection of Flu A + B CLIA waived kit · Becton, Dickinson & CO · Feb 24, 2016
- K152874 — BD Veritor System for the Rapid Detection of Flu A + B Laboratory kit · Becton, Dickinson and Co. · Oct 27, 2015
